Examkin

Question

Difficulty: MediumRheumatology and Immunology

A 74-year-old woman presents to the emergency department with a 3-day history of severe right-sided headache and jaw pain while chewing. She reports that 2 hours ago, she experienced sudden, painless vision loss in her right eye. Physical examination reveals a tender, nonpulsatile right temporal artery. Laboratory studies show an erythrocyte sedimentation rate of 110110 mm/h. Arrange the following diagnostic and therapeutic steps in the most appropriate chronological sequence for the management of this patient's condition, from immediate (first) to long-term (last).

  1. 1Administration of high-dose intravenous methylprednisolone
  2. 2Procurement of a temporal artery biopsy
  3. 3Initiation of a steroid-sparing agent (e.g., tocilizumab)
  4. 4Gradual tapering of the glucocorticoid dosage

Answer

The correct sequence is: 1) Administration of high-dose intravenous methylprednisolone, 2) Procurement of a temporal artery biopsy, 3) Initiation of a steroid-sparing agent, 4) Gradual tapering of the glucocorticoid dosage.
The correct chronological management of giant cell arteritis with visual loss prioritizes immediate vision preservation (intravenous steroids), followed by definitive diagnosis (temporal artery biopsy), transition to maintenance therapy (steroid-sparing agent), and finally, minimization of drug toxicity (glucocorticoid taper).

Step-by-Step Solution

1
Administer high-dose intravenous methylprednisolone
Prevention of further ischemic damage to the optic nerve
Patients with giant cell arteritis experiencing acute visual loss require immediate intravenous glucocorticoids before any diagnostic testing to salvage vision and prevent contralateral blindness.
2
Perform a temporal artery biopsy
Histologic confirmation of giant cell arteritis
Biopsy is the gold standard for diagnosis. It should be performed within 1 to 2 weeks of initiating steroids; waiting for the biopsy should never delay initial vision-saving treatment.
3
Initiate a steroid-sparing agent (e.g., tocilizumab)
Optimization of maintenance therapy
Tocilizumab is added to help maintain clinical remission and reduce the cumulative dose and toxicity of long-term glucocorticoids.
4
Gradually taper the glucocorticoid dosage
Minimization of long-term steroid adverse effects
Once disease activity is controlled and a steroid-sparing agent is on board, steroids are slowly tapered over several months while closely monitoring for symptom relapse and inflammatory marker elevation.

Key Concept

Chronological management sequence of Giant Cell Arteritis presenting with ischemic visual complications.
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic